TY - JOUR
T1 - Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas
T2 - results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830] (Annals of Oncology (2019) 30(11) (1821–1830), (S0923753420325904))
AU - Jhaveri, K. L.
AU - Wang, X. V.
AU - Makker, V.
AU - Luoh, S. W.
AU - Mitchell, E. P.
AU - Zwiebel, J. A.
AU - Sharon, E.
AU - Gray, R. J.
AU - Li, S.
AU - McShane, L. M.
AU - Rubinstein, L. V.
AU - Patton, D.
AU - Williams, P. M.
AU - Hamilton, S. R.
AU - Conley, B. A.
AU - Arteaga, C. L.
AU - Harris, L. N.
AU - O'Dwyer, P. J.
AU - Chen, A. P.
AU - Flaherty, K. T.
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2021/8
Y1 - 2021/8
N2 - The authors regret that Dr Arteaga's disclosures were not complete in the original publication. Dr Arteaga's full disclosure should read as follows: CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare. The authors would like to apologise for any inconvenience caused.
AB - The authors regret that Dr Arteaga's disclosures were not complete in the original publication. Dr Arteaga's full disclosure should read as follows: CLA: grant support: Pfizer, Lilly, Radius, PUMA Biotechnology, Bayer, Takeda, Symphogen; honoraria: advisory board/steering committee: Daiichi Sankyo, ABBVIE, Novartis, Lilly, Sanofi, Radius, Taiho Oncology, PUMA Biotechnology, Merck, H3Biomedicine, Symphogen, OrigiMed, Immunomedics, Petra Pharma, G1 Therapeutics, Athenex, Dr Arteaga receives compensation for his role in the Scientific Advisory Board of the Komen Foundation, unrelated to this work; stock options: Provista, Y-TRAP. LNH: patents, royalties, other intellectual property—Philips Healthcare. The authors would like to apologise for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85109941855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109941855&partnerID=8YFLogxK
U2 - 10.1016/j.annonc.2021.05.797
DO - 10.1016/j.annonc.2021.05.797
M3 - Comment/debate
C2 - 34099371
AN - SCOPUS:85109941855
SN - 0923-7534
VL - 32
SP - 1068
JO - Annals of Oncology
JF - Annals of Oncology
IS - 8
ER -